Pioneering breakthrough in the chemical synthesis of Interferon β-1a
Bachem and GlyTech achieved a pioneering breakthrough with the successful chemical synthesis of this protein featuring a specific, single glycosylation.
Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.